These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21623269)

  • 1. Complete radiological response of metastatic anaplastic lymphoma kinase-positive signet ring lung adenocarcinoma to systemic chemotherapy.
    Korpanty G; Mulligan N; Carney DN
    J Thorac Oncol; 2011 May; 6(5):963-5. PubMed ID: 21623269
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression.
    Takeda M; Okamoto I; Sakai K; Tanaka K; Terashima M; Nishio K; Nakagawa K
    Clin Lung Cancer; 2012 Mar; 13(2):157-9. PubMed ID: 22056890
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical response to crizotinib retreatment after acquisition of drug resistance.
    Matsuoka H; Kurata T; Okamoto I; Kaneda H; Tanaka K; Nakagawa K
    J Clin Oncol; 2013 Jul; 31(19):e322-3. PubMed ID: 23715571
    [No Abstract]   [Full Text] [Related]  

  • 4. Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC.
    Strimpakos AS; Banerji U; Thavasu P; Tsilimagou A; Psyrri A; Syrigos KN
    Oncology; 2015; 89(1):53-9. PubMed ID: 25766505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.
    Li S; Zhou F; Ren S; Zhou C
    Lung Cancer; 2014 May; 84(2):203-5. PubMed ID: 24636847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
    J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of systemic chemotherapy in a patient with mitochondrial myopathy and non-small-cell lung cancer.
    Catania C; Spitaleri G; Delmonte A; Giovannini M; Toffalorio F; Noberasco C; Bresolin N; Comi G; De Pas T
    J Clin Oncol; 2012 Aug; 30(24):e226-8. PubMed ID: 22711848
    [No Abstract]   [Full Text] [Related]  

  • 8. Synchronous double primary lung cancers with different response to pemetrexed.
    Umemura S; Yamane H; Yano T; Hoshika T; Shiote Y; Takigawa N; Suwaki T; Shirakawa A; Kamei H
    Anticancer Drugs; 2011 Jun; 22(5):473-6. PubMed ID: 21346552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subacute cutaneous lupus erythematosus associated with pemetrexed plus Carboplatin chemotherapy.
    González García A; Sifuentes Giraldo WA; Grillo Fernández E; Zea Mendoza A
    J Clin Rheumatol; 2014 Dec; 20(8):449-50. PubMed ID: 25417687
    [No Abstract]   [Full Text] [Related]  

  • 10. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
    Rodrigues-Pereira J; Kim JH; Magallanes M; Lee DH; Wang J; Ganju V; Martínez-Barrera L; Barraclough H; van Kooten M; Orlando M
    J Thorac Oncol; 2011 Nov; 6(11):1907-14. PubMed ID: 22005471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer.
    Okamoto I; Takeda K; Daga H; Miyazaki M; Yonesaka K; Kiyota H; Tsurutani J; Ueda S; Ichikawa Y; Takeda M; Sekiguchi R; Tominaga K; Enatsu S; Nambu Y; Nakagawa K
    Lung Cancer; 2010 Nov; 70(2):168-73. PubMed ID: 20236726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose escalation and pharmacokinetic study of carboplatin plus pemetrexed for elderly patients with advanced nonsquamous non-small-cell lung cancer: Kumamoto thoracic oncology study group trial 1002.
    Sakata S; Sasaki J; Saeki S; Hamada A; Kishi H; Nakamura K; Tanaka H; Notsute D; Sato R; Saruwatari K; Iriki T; Akaike K; Fujii S; Hirosako S; Kohrogi H
    Oncology; 2015; 88(4):201-7. PubMed ID: 25502447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
    Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
    Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE).
    Galetta D; Pisconti S; Cinieri S; Pappagallo GL; Gebbia V; Borsellino N; Maiello E; Rinaldi A; Montrone M; Rizzo P; Marzano N; Sasso N; Febbraro A; Colucci G
    Clin Lung Cancer; 2011 Nov; 12(6):402-6. PubMed ID: 21831718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma.
    Bailon O; Chouahnia K; Augier A; Bouillet T; Billot S; Coman I; Ursu R; Belin C; Zelek L; Des Guetz G; Levy C; Carpentier AF; Morere JF
    Neuro Oncol; 2012 Apr; 14(4):491-5. PubMed ID: 22362813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
    Casey EM; Harb W; Bradford D; Bufill J; Nattam S; Patel J; Fisher W; Latz JE; Li X; Wu J; Hanna N
    J Thorac Oncol; 2010 Nov; 5(11):1815-20. PubMed ID: 20881647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer.
    Dy GK; Bogner PN; Tan W; Demmy TL; Farooq A; Chen H; Yendamuri SS; Nwogu CE; Bushunow PW; Gannon J; Adjei AA; Adjei AA; Ramnath N
    J Thorac Oncol; 2014 Feb; 9(2):222-30. PubMed ID: 24419420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
    Lee JO; Kim TM; Lee SH; Kim DW; Kim S; Jeon YK; Chung DH; Kim WH; Kim YT; Yang SC; Kim YW; Heo DS; Bang YJ
    J Thorac Oncol; 2011 Sep; 6(9):1474-80. PubMed ID: 21642865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.